Dr. Stanislaw Burzynski received much-deserved publicity with the release of the 2011 film, Burzynski—The Movie.
Eric Merola’s award-winning documentary showcased Dr. Burzynski’s remarkable cancer discovery for all the world to see, and explained how he won the largest and possibly the most convoluted and intriguing legal battles against the Food and Drug Administration (FDA) in American history.
Dr. Burzynski’s story now continues in the compelling follow-up film: Burzynski—Cancer Is Serious Business, Part II. This second film details his continued struggles and victories and explores the current status of Antineoplastons’ clinical testing—now (finally) sanctioned by the FDA.
Dr. Burzynski’s Cancer Treatment
Dr. Burzynski, trained as both a biochemist and a physician, has spent the last 35+ years developing and successfully treating cancer patients suffering from some of the most lethal forms of cancer at his clinic in Houston, Texas.
The treatment he developed involves a gene-targeted approach using non-toxic peptides and amino acids, known as Antineoplastons. I personally interviewed Dr. Burzynski about his treatment in the summer of 2011.
He coined the term ”antineoplastons” and defines them as peptides and derivatives of amino acids that act as molecular switches. However, as genome research blossomed and science progressed, Dr. Burzynski discovered that antineoplastons also work as genetic switches.
They actually turn off the genes that cause cancer (oncogenes), and turn on or activate tumor suppressor genes—genes that fight cancer. His treatment strategy, which he refers to as “Personalized Gene-Targeted Cancer Therapy,” includes mapping the patient’s entire cancer genome.
This involves analyzing some 24,000 genes in order to identify the abnormal genes. Once they’ve determined which genes are involved in the cancer, drugs and supplements are identified to target those specific genes.
Antineoplastons work on approximately 100 cancer-causing genes, but traditional oncology agents (including chemotherapy) may also be used, typically in combination with antineoplastons. This expanded direction of “personalized gene-targeted treatment” has permitted people who would otherwise be denied access to the still-unapproved antineoplastons to benefit from his treatment.
The War on Cancer Cures
As the first film in this series clearly revealed, the FDA began scheming to eliminate the threat Dr. Burzynski and his discovery posed to the cancer industry as early as 1977, when Dr. Burzynski first tried to get antineoplastons approved.
The reason he was (and still is) considered a significant threat to the cancer industry is because he’s the sole patent holder of the treatment, which means he’s the sole beneficiary, should the FDA approve Antineoplastons—not a pharmaceutical company and the bosses thereof.
As a matter of fact, Dr. Burzynski is the first and only scientist in United States’ history to enter the federal drug approval process for a proprietary cancer therapy without any financial support from the American government, the pharmaceutical industry, or the cancer establishment.
Vast amounts of money are at stake since FDA approval of Antineoplastons would not only threaten conventional chemotherapy and radiation, it would also result in billions of dollars of cancer research funds being funneled over to the one single scientist who has exclusive patent rights—Dr. Burzynski.
The sad fact is, as stated by Dr. Julian Whitaker in the featured film, that true medical breakthroughs are suppressed these days because they “put at risk the entire financial underpinnings” of medicine.
If a medical breakthrough replaces failing therapies, the cash flow and profits of those failing therapies are lost forever, and the industry simply chooses profits over cures… Instead of investing in actual cures, medicine, over the past five decades, has invested in awareness campaigns. But, as Dr. Whitaker points out, awareness does not cure the disease, and will never lead to a cure, no matter how much money is raised by these campaigns, for the simple fact that there’s too much vested-interest in therapies that fail and perpetuate a money-making disease.
Cancer Is Serious Business
In recent years, the focus for cancer therapy has increasingly shifted toward individualized gene-targeted cancer treatment, such as that provided by Dr. Burzynski for the past decade. So it’s no wonder, really, that the industry has tried so hard to get rid of him, in order to protect their own profits and access to research funds. Burzynski—Cancer is Serious Business, picks up where the first movie left off, detailing Dr. Burzynski’s continued struggles and victories and explores the current status of Antineoplastons’ clinical testing, now sanctioned by the FDA. It also follows the progress of several of his patients. As described in the film’s synopsis:1
“For most patients undergoing Burzynski’s treatment, their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists but also from friends and family who feel their loved ones are making suspect treatment decisions—even though mainstream oncology has already left many for dead.
As the story unfolds, you will observe a real-time change of hearts and minds from many of these doctors and families. Unlike the first documentary, Part II showcases interviews with board-certified oncologists, surgeons, and neurosurgeons, who witnessed patients leave their care, soon to return in great health after opting for the Burzynski Clinic.”
National Cancer Institute Acknowledges Antineoplastons’ Success
Incredibly, in August of last year, America’s National Cancer Institute (NCI) finally acknowledged and cited some of Burzynski’s peer-reviewed Antineoplaston studies, as well as findings by Japanese researchers who have been independently reproducing Antineoplaston clinical trial studies since the 1980s, without any involvement by Dr. Burzynski. One of the most remarkable admissions by The National Cancer Institute is the following:2
“A Phase II study also conducted by the developer and his associates at his clinic reported on 12 patients with recurrent diffuse intrinsic brainstem glioma. Of the 10 patients who were evaluable, two achieved complete tumor response, three had partial tumor response, three had stable disease, and two had progressive disease.”
What’s truly remarkable about this is that a brainstem glioma has simply never been cured before in the history of medicine—Antineoplastons hold the first cures ever! In the feature film, you will also learn how a Japanese team, consisting of pathologists, oncologists, and surgeons, has conducted the first-ever independently-run randomized controlled human clinical trials on Antineoplastons, and the results thereof. According to Dr. Hideaki Tsuda, MD with the Kurume Medical University in Japan:
“After 27 years of independently testing Antineoplastons—including randomized clinical trials, we found that Dr. Burzynski was right. It’s obviously not anecdotal anymore.”
The Story Everyone Needs to Know
Dr. Burzynski has developed a cancer treatment that surpasses all other treatments on the market today, and the FDA and the pharmaceutical industry knows it. They also know his treatment threatens the entire paradigm of the cancer industry, which is based on expensive treatments with a high rate of failure and retreatment.
For the past 15 years, they’ve harassed him, tried to take away his medical license, and even tried to put him in prison for life—all in order to protect the status quo. Adding insult to injury, you and I have been paying for the brutal opposition to Dr. Burzynski’s cancer treatment this whole time. The US government spent $60 million on legal fees for just one of his trials alone.
Still, Dr. Burzynski has prevailed, and the truth about his gene-targeted treatment is finally receiving some well-deserved acknowledgment. After all, Dr. Burzynski has published over 300 articles on Antineoplastons, many of them peer-reviewed. And more than 100 independent Antineoplaston studies have been published, including those from Japan.
Support a Cancer Cure, Not Merely the Awareness of the Condition
Earlier this year, a group of patients and patient advocates launched a campaign to have Antineoplastons accepted worldwide as a “standard of care” for the treatment of cancer.3 For more information, please see www.iwantanp.com:
“Unlike all other cancer research campaigns which rely 100% on awareness alone, we realize that awareness itself does not cure the disease. Medications such as Antineoplastons are what can lead to the cure of the disease of cancer.
If the United States still refuses to allow Antineoplastons into its marketplace, we will then make sure another country will be properly funded to set up the proper channels for Antineoplastons to be approved for their marketplace. Another avenue would be simply opening up a massive Antineoplastons clinic allowing the cancer patients of the world to seek treatment using Antineoplastons.
Upon gaining either market approval—or the funding the construction of an Antineoplaston clinic overseas, our funds will then go to make sure everyone who cannot afford to travel overseas to receive Antineoplaston therapy—can do so by requesting money through this organization.
Either way, whether the market or its government’s regulatory agencies want Antineoplastons available to its citizens or not—Antineoplastons are here to stay, and the members of our global human family deserve the right to have access to them.”